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Heart Disease and Pulmonary Arterial
Hypertension in the UK: Survey of
Current Practice, Unmet Needs and Expert
Commentary
Robert Tulloh, FRCPCH, DMa*, Kostas Dimopoulos, MRCP, PhDb,
Robin Condliffe, MRCP, MDc, Paul Clift, MRCP, MDd,
on behalf of The CHAMPION Steering Committee
aDepartment of Congenital Heart Disease, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
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cPulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
dDepartment of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UKReceived 8 May 2017; received in revised form 22 October 2017; accepted 29 October 2017; online published-ahead-of-print 13 November 2017Background Pulmonary arterial hypertension (PAH) is a well-recognised complication of adult congenital heart disease
(CHD). However, management is not currently standardised between centres and specific guidelines are
lacking. In order to identify and understand the unmet needs related to PAH associated with CHD (PAH-
CHD), a survey of physicians was performed.
Methods An electronic survey was sent to two physician groups: (1) cardiologists registered in a UK cardiology
directory; (2) specialist pulmonary hypertension (PH) physicians known to manage patients with adult
PAH-CHD. The questions related to referral pathways, screening, therapy and palliative care.
Results 821 surveys were distributed and 106 were returned. Respondents included a broad mix of specialist
physicians with many patients along with general cardiologists managing only a small number of PAH-
CHD patients. Although 97% of respondents have access to a specialist PH centre, patients are still being
managed in non-specialist settings. Shared care arrangements are widespread but only 41% have formal
shared care protocols. Palliative care services are limited and general cardiologists rarely perform 6-minute
walk tests (6MWT) or quality of life assessments. People with PAH-CHD are often undertreated, with 39%
of respondents reporting that fewer than 25% of these patients were receiving PAH-specific therapies.
Conclusions The survey revealed gaps and inconsistencies in the management of patients with PAH-CHD therefore
patient-specific guidance is needed for many of these aspects.
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Table 1 Respondent characteristics.
Characteristica n/N %
Geographic region of practice
North 5/32 16
Midlands and East 6/32 19
South, excluding London 12/32 38
London 3/32 9
Scotland 4/32 13
Northern Ireland 0/32 0
Wales 2/32 6
Speciality
General physician 0/32 0
Rheumatologist 0/32 0
Respiratory physician 2/32 6
General cardiologist 18/32 56
ACHD cardiologist 12/32 38
Paediatric cardiologist 0/32 0
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Pulmonary arterial hypertension (PAH) is defined as a mean
pulmonary arterial pressure of 25 mmHg at rest, with a
pulmonary artery wedge pressure or left atrial pressure
15 mmHg and pulmonary vascular resistance (PVR) >3
Wood units [1–3]. Congenital heart disease (CHD) that
causes unrestricted pressure and volume overload of the
pulmonary circulation can lead to PAH [4]. Recent paediatric
medical and surgical advances have enabled people with
CHD to live longer, leading to an increase in the number
of patients who go on to develop PAH associated with CHD
(PAH-CHD) [3]. The 2015 UK audit of specialised PH centres
reported a rate of 17 people with PAH due to CHD per
million of the population [5]. Five to ten per cent of adults
with CHD also have PAH [1,2].
The European Society of Cardiology/European Respira-
tory Society (ESC/ERS) guidelines provide recommenda-
tions for the management of PAH-CHD [1,2]. However,
evidence to support the use of PAH-specific therapies in
CHD is limited and the management is not standardised,
with variation between treating centres and clinicians.
The Congenital Heart disease And pulMonary arterial
hyPertension: Improving Outcomes through education and
research Networks (CHAMPION) program was set up to
improve the care of patients with PAH-CHD in the UK
and to help inform clinician decision-making. Objectives
include identification of evidence gaps, unmet needs, chal-
lenges associated with the management, and development of
educational resources and initiatives to ensure sharing of
best practice. Within this remit, a survey was conducted to
gain an understanding of the challenges faced by physicians
in the day-to-day management of PAH-CHD in the UK. This
publication covers various aspects of patient management,
presenting the survey results and providing expert commen-
tary on each aspect.Years in practice
<5 years 0/32 0
5 to 15 years 4/32 13
>15 years 28/32 88
Years in practice as a consultant
<5 years 8/31 25
5 to 15 years 13/31 41
>15 years 10/31 31
Approximate number of PAH-CHD patients seen annuallyb
<10 23/55 42
10 to 49 14/55 26
50 to 100 13/55 24
>100 5/55 9
n/N: Number of respondents with each characteristic/Total number of
respondents who completed the question.
Abbreviations: ACHD, adult congenital heart disease; PAH-CHD, pul-
monary arterial hypertension associated with congenital heart disease.
aNot all respondents provided demographic information.
bRespondents were asked to specify for the year 2015.Methods
Respondents and Inclusion/Exclusion
Criteria
The survey targeted both general cardiologists and experts in
PAH-CHD and therefore included two groups of clinicians:
those proposed by the CHAMPION Steering Committee as
currently managing these patients, and all adult cardiologists
registered with the UK Directory of Cardiology (http://
cardiodirectory.co.uk) with an email address. This second
source was used to ensure that physicians who manage PAH-
CHD outside specialist centres were also identified and
included. At the start of the survey, consenting respondents
were asked to confirm whether they worked in a general
cardiology department, specialist adult CHD centre or spe-
cialist PH centre, and that they managed PAH-CHD. Other
respondents were excluded from the survey. An introduc-
tory email, followed by two reminder emails, was sent to allparticipants together with a hyperlink to the survey. All
responses were anonymised, but some demographic infor-
mation was requested and analysed.
Survey
The survey was electronically administered using a profes-
sional survey website (SurveyMonkey, Palo Alto, CA, USA)
(see Supplementary Figure S1 for survey questions). Ques-
tions were either multiple choice or answered by five-point
Likert scales or free text comment boxes. Prior to the survey, a
pragmatic literature review of PAH-CHD was performed
and used by the CHAMPION Steering Committee to identify
unmet needs related to their care. As part of the survey,
respondents were asked to rank these unmet needs in order
of importance. For each unmet need, weighted averages were
calculated by assigning five points for each first place
Table 2 Unmet needs identified by the Steering Committee: Ranking by survey respondents.
Unmet needs and rank (n = 30) Ranka %b Weighted averagec
Development of a standardised approach to the care of PAH-CHD patients across centres 1 60 3.3
Establishment of a screening protocol for PAH in CHD patients 2 53 3.7
Definition of treatment targets for different PAH-CHD subgroups 3 53 2.6
National guidance on when to initiate and escalate PAH-specific therapies in PAH-CHD patients 4 50 3.3
Guidance on risk stratification for PAH-CHD patients 5 47 3.4
Guidance on how to manage non-Eisenmenger’s syndrome patients 6 40 3.1
Guidance on non-pharmacological therapy for PAH-CHD patients 7 40 2.8
Establishment of a registry to determine the size and characteristics of the PAH-CHD population 8 33 3.1
Palliative care strategy 9 33 2.8
Identification of biomarkers and other non-invasive strategies for screening CHD patients for PAH 10 30 2.4
Management of Down’s syndrome patients 11 27 2.4
Creation of a biobank of CHD samples for genomic analysis 12 20 2.0
n: Number of respondents who completed the question.
Abbreviations: PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; PAH, pulmonary arterial hypertension; PH, pulmonary
hypertension; CHD, congenital heart disease.
aRanking was assigned in descending order according to % of respondents who indicated the unmet need within their top 5, followed by weighted average in cases
where % was identical.
b% of respondents who indicated that this was one of their top 5 unmet needs.
c5 points were assigned for each 1st place ranking, 4 points for each 2nd place ranking, 3 points for each 3rd place ranking, 2 points for each 4th place ranking and 1
point for each 5th place ranking. The average was calculated by dividing by the total number of points assigned to each unmet need by the total number of
respondents who provided a ranking for that need.
1020 R. Tulloh et al.ranking, four points for each second place, etc. The total was
divided by the number of respondents in order to determine
an average ranking for each unmet need. Categorical values
were presented as numbers (percentage).Results and Expert Commentary
Respondent Characteristics
A total of 821 physicians were invited to participate in the
survey and 106 responded. Demographic information is
shown in Table 1. The proportion of respondents managing
more than 50 people with PAH-CHD per year was 33%,
hence many worked in a specialised setting. However,
56% of respondents described themselves as general cardi-
ologists and 42% of respondents managed less than 10 people
with PAH and CHD annually. Four of the respondents were
from a PAH specialist centre. We have shown that 47% of
respondents were from the South and London, where the
majority of specialist PH centres are located. Eighteen of 55
(33%) of respondents saw >50% PAH-CHD patients annu-
ally, of these 5/18 (28%) stated that they worked in a general
cardiology department (so therefore were NOT either PH
specialists or ACHD specialists).
Unmet Needs in the Management of
Pulmonary Arterial Hypertension
Associated with CHD
The unmet needs in the management of people with PAH-
CHD were previously identified by the Steering Committee.When asked to rank these, respondents were in broad agree-
ment (Table 2). The five unmet needs considered to be most
important by the Steering Committee are discussed below.
Standardised Approach to Care
Seven adult and one paediatric centre were designated in
2001 to provide specialist PH services in the UK (see Sup-
plementary Table S1). Each centre has to meet standards
including the use of specialist nurses and expert consultants
providing 24-hour care, prescription and monitoring of PAH
therapies in addition to collection of data for the annual UK
National PH audit. Furthermore, the National Health Ser-
vice, England recently conducted a review of CHD services
in order to standardise patient care [6]. Current UK adult
CHD services comprise regional networks of specialist adult
CHD (including surgical) and local adult CHD centres. The
proportion of respondents who referred people with PAH-
CHD to a specialist PH centre was 97% (57% of whom were
general cardiologists and respiratory physicians) (see Table
3). The majority of respondents (81%) share the management
of patients with a specialist PH centre, with 56% of respond-
ents reporting having a shared care clinic within their own
unit. Shared care is driven by physicians with an interest in
PH, enabling the diagnosis, prescribing and monitoring of
people with PAH-CHD to be provided at the patient’s adult
CHD centre. Formal shared care protocols were in place in
only 41% of shared care clinics (see Table 3), revealing a lack
of adherence to the recommendations outlined in the 2015
New CHD review, which states that all Level one and Level
two adult CHD centres are required to have evidence of joint
protocols of care with a national PH centre [6].
Table 3 Referral/care pathways for PAH-CHD patients.
Elements of care Respondents who answered yes
n/N %
Do your PAH-CHD patients attend the following types of clinic?a
General cardiology clinic 15/44 34
Specialist ACHD clinic 27/44 61
Specialist PAH-CHD clinic 23/44 52
General PH clinic 6/44 14
In your centre do you refer patients to a specialist PH service?
35/36 97
Do you share management of patients with a specialist PH service?
29/36 81
Do you have a shared care clinic within your own unit?
18/32 56
Do you have a written, formal shared care protocol with a specialist PH centre?
13/32 41
Do your PAH-CHD patients have access to the following specialist staff?
Nominated PAH clinician 27/44 61
PAH specialist nurseb 14/42 33
PAH specialist pharmacist 8/42 19
n/N: Number of respondents who answered yes/Total number of respondents who completed the question.
Abbreviations: PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; PAH, pulmonary arterial hypertension; PH, pulmonary
hypertension; ACHD, adult congenital heart disease.
aRespondents could specify more than one type of clinic.
bIncluded only responses that stated  1 full time equivalent nurse.
Table 4 Screening for PAH in CHD patients.
Aspects of Screening Respondents who answered
yes
n/N %
Do you consider PH when evaluating each of the following
groups of patients?a
ASD 34/36 94
VSD 34/36 94
Systemic to pulmonary shunts35/36 97
Operated left to right shunts 30/36 83
Complex defects 33/36 92
Other 3/36 8
When do you screen CHD patients for PAH?
First evaluation only 3/36 8
Every time I review them 22/36 61
Periodically 11/36 31
n/N: Number of respondents who selected this option/Total number of
respondents who completed the question.
Abbreviations: ASD: atrial septal defect; CHD: congenital heart disease;
PAH: pulmonary arterial hypertension; VSD: ventricular septal defect.
aRespondents could specify more than one group of patients.
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standardised approach to the care of PAH-CHD as one of
their top five unmet needs was 60% (Table 2) and highlighted
the need for clearer referral pathways and easier access to
specialist PH centres (see Supplementary material survey
data slides). Furthermore, although 61% of respondents
reported that patients had a nominated PH physician, spe-
cialist PH nurses and specialist pharmacists were reported by
only 33% and 19% of respondents respectively as being
available, indicating that certain aspects of specialist care
are lacking (Table 3). Current ESC/ERS guidelines recom-
mend that specialist PH centres should follow at least 50
patients on PAH treatment with at least two new referrals per
month [1,2]. They should be able to offer full diagnostic
services including computerised tomography, magnetic res-
onance imaging and right heart catheterisation and should
have specialist nurse support [1,2]. Furthermore, they should
be able to offer all PAH therapies available in that country
and should also enrol patients in clinical trials [1,2]. Although
specialist adult CHD centres may be able to fulfil many of
these requirements, they may not be able to offer more
complex therapies such as therapies targeting the prostacy-
clin pathway and, therefore, a clear referral link with a
designated PH centre is vital.
Table 5 Therapy recommendations for PAH-CHD patients.
PAH-CHD classification Recommended treatments ESC/ERS
recommendation
(class/level of
evidence) [1,2]
Evidence to date
Eisenmenger’s syndrome Bosentan [1,2] IB BREATHE 5 [21] + BREATHE 5 OLE [22]
Eisenmenger’s syndrome Other ERAs, PDE5is and prostanoids should be
considered [1,2]
IIaC Data from retrospective, observational
studies and small RCTs [23–27]
PAH associated with
prevalent systemic to
pulmonary shunts
Selected cases may benefit from closure. As data
are lacking, no recommendations can be made
for or against the use of PAH-specific therapies
[4]
NA Data from observational study [23]
PAH with small/
coincidental
defectsa
Avoid defect closure, treat with PAH-specific
therapies [4]
NA Data from RCTs and observational
study [23,28]
PAH after defect
correction
Do not close residual defects. Treat with PAH-
specific therapies [4]
NA Data from RCTs with PAH-CHD
subgroup [29–34]. Data from
observational study [23]
NA: No specific recommendations are provided in the ESC/ERS Guidelines.
Abbreviations: ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ERS, European Society for Cardiology; OLE, open label extension; PAH,
pulmonary arterial hypertension; PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; PDE5i, phosphodiesterase type 5
inhibitor; RCT, randomised controlled trial; BREATHE 5, The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5.
aMany patients with small defects are considered to be idiopathic PAH patients with a coexistent defect and hence are eligible for treatment.
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The importance of identifying CHD patients with a high PVR
has long been accepted [7]. This is achieved by estimating
pulmonary artery pressure on echocardiography and refer-
ring for cardiac catheterisation. It, therefore, comes as no
surprise that physician awareness of the potential for pul-
monary vascular disease in CHD is high, with more than 90%
of respondents reporting that they screen all patients with
atrial septal defects, ventricular septal defects, systemic-to-
pulmonary shunts and complex defects and 83% screen
patients with repaired left-to-right shunts for late develop-
ment of PH (Table 4). Furthermore, 92% of respondents
screen patients either periodically or at every clinic visit,
with just 8% only screening for PAH at the initial clinic visit
(Table 4). These data confirm that clinicians managing CHD
routinely assess pulmonary haemodynamics; such screening
should remain part of the long-term management of these
patients.Initiation and Escalation of Therapy/
Risk Stratification
Table 5 summarises therapy recommendations for PAH-
CHD patients. The survey revealed that many people with
PAH-CHD are not receiving treatment, with almost 40% of
respondents reporting a low usage of PAH-specific therapies
(defined as less than 25% receiving a PAH-specific therapy)
(Table 6). The proportion of respondents reporting low usage
of PAH-specific therapies was greater among those working
in general cardiology departments than among thoseworking in specialist adult CHD centres (49% versus 18%,
respectively) (Figure 1). These data suggest that patients may
benefit from further assessment in a specialist setting. Over
half (56%) of respondents with a high case load of
Eisenmenger’s syndrome (defined as more than 50% of their
PAH patients) reported high or very high usage of PAH-
specific therapies (defined as 50–74% or 75–100%), as com-
pared with 30% (17/56) for all respondents combined. Con-
versely, among respondents with prevalent systemic-to-
pulmonary shunts accounting for more than 50% of all peo-
ple with PAH-CHD, only 11% (1/9) reported high or very
high usage of PAH-specific therapies. This reflects differ-
ences in the guidance for PAH-specific therapies for each
of the CHD subtypes.
To further explore how therapy is initiated and managed
in people with PAH-CHD, the survey respondents were
asked whether they initiate and/or manage therapy, or
whether they refer all patients who need PAH-specific ther-
apy to a PH specialist. Over half (54%) of respondents
stated that they initiate and/or manage specific therapies
(Table 6). Of these, 35% reported both initiating and manag-
ing specific therapies, while the remainder only manage
therapies after initiation by another clinician. The survey
indicates that therapy is more likely to be initiated by physi-
cians working in specialist centres than in general cardiology
departments; 65% of respondents from specialist adult
CHD centres both initiate and manage PAH-specific thera-
pies, whereas this was only true for 15% of respondents
working in general cardiology departments, possibly leading
to under-treatment.
Table 6 Management of PAH-specific therapy in PAH-CHD patients.
Aspects of PAH-specific therapy management Respondents
n/N %
Approximately what percentage of your PAH-CHD patients are currently receiving a PAH-specific therapy?
0 to 24% 22/56 39
25 to 49% 17/56 30
50 to 74% 14/56 25
75 to 100% 3/56 5
Do you initiate and manage PAH-specific therapies for patients with PAH-CHD?
Yes, both initiate and manage 22/63 35
Yes, manage but not initiate 12/63 19
No, I refer all patients who need PAH specific therapies to a PH specialist 29/63 46
Which therapies do you initiate/manage?a
Sildenafil 30/30 100
Bosentan 25/30 83
Ambrisentan 20/30 67
Macitentan 16/30 53
Tadalafil 15/30 50
Riociguat 7/30 23
Iloprost i.v. 7/30 23
Epoprostenol i.v. 6/30 20
Iloprost inhaled 5/30 17
Treprostinil s.c. 1/30 3
Treprostinil i.v. 1/30 3
Vardenafil 0/30 0
Do you perform walk tests for your PAH-CHD patients?
Yes 25/41 61
No 16/41 39
Do you measure quality of life for your PAH-CHD patients?
Yes 19/40 50
No 20/40 50
n/N: Number of respondents who selected this option/Total number of respondents who completed the question.
Abbreviations: i.v., intravenous; PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; PH, pulmonary hypertension; s.c.,
subcutaneous.
aRespondents could specify more than one therapy.
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respondents who initiate/manage therapy) (see Table 6).
This frequent use is likely due to the fact that bosentan is
the only therapy with a class I recommendation in
Eisenmenger’s syndrome patients in the ESC/ERS guidelines
[1,2]. A current trial is being undertaken with macitentan
(MAESTRO, Clinical study to assess the efficacy, safety, and
tolerability of macitentan in subjects with Eisenmenger Syn-
drome; ClinicalTrials.gov Identifier: NCT01743001) and
should report in 2017. All respondents reported managing
patients using phosphodiesterase type 5 inhibitors, which
is likely the result of the wide availability of sildenafil, low
cost and clear commissioning guidance supporting sildenafil
as first-line treatment for all PAH patients in the UK; 67% and
53% of respondents reported that they also managed patients
with the endothelin receptor antagonists ambrisentan andmacitentan, respectively. In total, 43% of respondents
reported that they managed their patients using prostanoids
(Table 6). A greater use of prostanoids was reported among
specialist PH and adult CHD centres (61%) versus general
cardiology clinics (15%).
Once a patient with PAH has been initiated on therapy, the
current ESC/ERS guidelines recommend regular assessment
in specialist PH centres to collect prognostic information,
including exercise testing, which allows stratification of
patients in a low (estimated 1-year mortality <5%), interme-
diate (estimated 1-year mortality 5 to 10%) or high risk
(estimated 1-year mortality >10%) group. If patients do
not meet their treatment goals, and their response to therapy
is deemed inadequate, the treatment regimen should be
escalated [1,2]. In the current study, 39% of respondents
(the majority working in general cardiology units) reported
Figure 1 Proportion of PAH-CHD patients treated with PAH-specific therapies, classified according to the type of practice.
Abbreviations: ACHD, adult congenital heart disease; PAH-CHD, pulmonary arterial hypertension associated with con-
genital heart disease.
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performed in specialist PH centres (Table 6). In this survey,
50% of respondents also stated that they do not perform
quality of life assessments (90% of these worked in general
cardiology units). Quality of life is an important treatment
goal in PAH [1,2] and a decreasing quality of life has been
shown to be a determinant of mortality in people with PAH-
CHD [8], highlighting the need for regular assessment.
There were four responses from PH specialists. One was
not managing PAH-CHD patients so did not proceed with
the survey beyond q. 2 and another did not proceed beyond
q. 4: Which therapies do you initiate/manage. Therapies
initiated or managed were: Respondent 1: bosentan, maci-
tentan, iloprost i.v., iloprost inhaled, treprostinil; respondent
2: bosentan, macitentan, ambrisentan, epoprostenol i.v., ilo-
prost inhaled. Both respondents saw 50–100 patients annu-
ally and for respondent 1, 50–74% were on PAH specific
therapy, and for respondent 2, 0–24% were. Both performed
the 6MWT twice a year and both used the emPHasis-10
quality of life questionnaire.
In summary, the results of this survey indicate that many
patients with PAH-CHD are not being treated with PAH-
specific therapies. This may, in part, be because many
patients are still managed in general cardiology clinics.
The ESC/ERS guidelines recommend that PAH care should
take place in specialist PH centres that routinely manage
PAH-specific drug therapies and can prescribe all such
therapies available in a particular country [1,2]. Patients
who are managed in non-specialist centres may have less
access to therapy, have lower awareness of available treat-
ment options and do not routinely undergo exercise testingand quality of life assessment. Improving referral pathways
and access to specialist centres, both raised as issues to be
addressed by the survey respondents, may lead to an
increase in the use of PAH-specific therapy for people with
PAH-CHD. The lack of specific treatment recommendations
for PAH-CHD subtypes other than Eisenmenger’s syn-
drome needs to be addressed.
Non Pulmonary Arterial Hypertension-
Specific Therapy
Non-pharmacological and supportive therapy are impor-
tant components of the clinical management of PAH. This is
reflected in the results of the current survey, with 40% of
respondents stating that more information was needed on
non-pharmacological management (Table 2). Furthermore,
when asked to describe their top issues in management of
PAH-CHD, respondents mentioned issues such as preg-
nancy and birth control, iron deficiency, exercise, anticoa-
gulation, dental/skin care, arrhythmias and role of
venesection.
There are currently no national protocols for the non-
pharmacological management of PAH-CHD, however, rec-
ommendations are given in the ESC/ERS guidelines [1,2].
Pregnancy is associated with substantial mortality in PAH
patients [9] and therefore should be avoided [1,2]. Most
clinicians would recommend Mirena coil and progester-
one-only preparations for contraception. As people with
PAH are often iron-deficient, they should undergo regular
monitoring of iron status and haemoglobin levels due to the
potential impact of iron deficiency on exercise capacity and
mortality [1,2]. If iron replacement therapy is required it may
Management of adults with congenital heart disease and pulmonary arterial hypertension 1025need to be given intravenously due to poor oral absorption or
intolerance [1,2,10]. When a patient is diagnosed, a degree of
realistic expectation management is required for activities
related to daily living. It is often necessary for patients to
adapt their lifestyle to avoid strenuous exercise and some-
times to alter their working patterns in order to still have the
maximum quality of life. The current ESC/ERS guidelines
recommend that patients should undertake supervised phys-
ical activity within the limits of symptoms [1,2]. It is impor-
tant for patients to avoid activity that causes syncope or
severe breathlessness, but there is mounting evidence that
‘keeping fit’ is an important adjunct to pharmacological
treatment [11,12]. Currently, it is not known which method
of exercise rehabilitation should be used or the intensity and
duration of exercise that should be applied [1,2]. No study
has yet determined whether exercise-training programs
improve prognosis. An exercise regime will therefore need
to be tailored to the individual patient, with realistic
expectations.
The most common arrhythmias seen in patients with PAH-
CHD are atrial flutter (often relating to sites of previous
incisions due to cardiac surgery) and ventricular tachycardia
(resulting from postoperative chronic fibrosis, hypoxia or
chronic volume loading) [13,14]. Both conditions require
input from cardiac electrophysiologists and are poorly toler-
ated. The consensus view is that therapy involving high dose
beta blockade should be avoided in patients with PAH, since
it impairs their ability to generate an increased heart rate
during exercise, impairs right ventricular function and can
lead to symptoms of severe breathlessness [15]. Venesection
is generally not recommended in PAH-CHD since it rendersTable 7 Palliative care in PAH-CHD patients.
Aspects of palliative care Resp
n/N 
Do you currently have a formal palliative care service for PAH-CHD p
Yes 6/33
No 27/3
When do you refer PAH-CHD patients to a palliative care service?a
On diagnosis 0/6 
After repeated hospitalisations 5/6 
Upon deterioration to FC IV 5/6 
Upon listing for transplantation 0/6 
Life expectancy <6months 6/6 
Other 3/6 
Do you think a palliative care service would be useful or valuable for 
Yes 22/2
No 5/27
n/N: Number of respondents who selected this option/Total number of responden
Abbreviations: FC: functional class; PAH-CHD: pulmonary arterial hypertension a
aRespondents could specify more than one time point and only respondents who rep
bOnly respondents who reported not having a formal palliative care service for PAthe patient iron deficient and may actually be associated with
an increased risk of stroke. It should only be performed, with
isovolumetric fluid replacement, when there are symptoms
of hyperviscosity [1,2]. Unlike patients with idiopathic PAH,
those with PAH-CHD are generally not anticoagulated, as
they are prone to bleeding from dilated bronchial arteries
and often have a low platelet count [1,2,16].
General management measures are essential to improving
both PAH-CHD outcomes and quality of life [4]. The ESC/
ERS guidelines offer clear guidance on non-pharmacological
management of PAH, but at the current time no specific
guidance is given for people with PAH-CHD and as not
all general measures are applicable to this patient subgroup,
specific guidelines are warranted.
Palliative Care
The current ESC/ERS guidelines recommend proactive
advanced care planning with timely referral of PAH patients
to palliative care services [1,2]. A large proportion of physi-
cians (82%) surveyed report having no formal palliative care
service for PAH-CHD, but 81% of these feel that a service of
this nature would be valuable to management (Table 7). To
address this unmet need, it is recommended that each centre
should have a palliative care service available, providing
good quality end of life care. Of the 18% of physicians
who do have a formal and appropriate palliative care service,
all would consider referring a patient with a life expectancy
of <6 months and 83% would also consider referral following
repeated hospital admissions and/or deterioration to func-
tional class IV. None of the respondents refer patients to
palliative care at the point of diagnosis. There is, therefore,ondents who answered yes
%
atients at your centre?
 18
3 82
0
83
83
0
100
50
the management of PAH-CHD patients in your practice?b
7 81
 19
ts who completed the question.
ssociated with congenital heart disease.
orted having a formal palliative care service were able to answer this question.
H-CHD patients were able to answer this question.
1026 R. Tulloh et al.a gap in the provision of palliative care services and a need
for guidance on the timing of referral to palliative care ser-
vices [17–19]. Earlier referral to palliative care should be
made when considering escalation of targeted vasodilator
therapy.
Study Limitations
There are several limitations to this study, which are related
to the electronic nature of the survey. The survey was
optional and therefore the physicians, who responded
(13%), may have been more likely to be those who considered
themselves to be knowledgeable in the field or who held
strong opinions on the subject. There might have been poten-
tial selection bias, if the survey was too lengthy for busy
clinicians. The demographic data, however, indicated that
responses were obtained from a broad range of physicians
including both PH specialists and general cardiologists. Fur-
thermore, the low response rate was not unexpected as PAH
is a rare disease (only 1000 people with PAH associated with
CHD were seen by the UK PH service in 2014) [20].
The survey results could have been affected by recall bias.
However, over a quarter of respondents (26.3%) stated that
they were using a database to answer the survey questions.
This is likely to increase the reliability of the results.Conclusions
Our survey managed to capture both general cardiologists
and physicians working in close cooperation with PH
centres. It demonstrated that physicians who were seeing
a large number of patients with Eisenmenger’s syndrome
were more likely to initiate and manage patients with
advanced PH therapy, and they were more likely to follow
guidelines. In addition, the survey revealed a gap in the
knowledge base for many therapies for patients with
PAH-CHD. There might be other confounders, such as a
patient or carer wish not to start therapy, but we did not
see a reason why there might be a geographical variation in
this but accept that there might be unrecognised alternative
possibilities as to why the standard guidelines were not
followed. This might even be more prevalent in a greater
geographical area outside of this study, with the effect of cost
containment, or other restrictions being in place.
General cardiologists report the need for improved guide-
lines and increased access to specialist care for their patients
with PAH-CHD. Efforts are needed to increase referral of
such patients into PH services by developing referral criteria
and to identify a best practice protocol for screening patients
with CHD for the presence of PAH.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at https://doi.org/10.1016/j.hlc.2017.
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